Evogene Ltd. (NASDAQ:EVGN) Sees Significant Increase in Short Interest

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 53,600 shares, an increase of 8.5% from the May 31st total of 49,400 shares. Based on an average daily volume of 77,400 shares, the short-interest ratio is presently 0.7 days.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Evogene in a research note on Thursday, June 27th. They set a “sell” rating for the company.

Evogene Stock Performance

NASDAQ EVGN opened at $0.64 on Thursday. The firm has a 50 day simple moving average of $0.69 and a 200-day simple moving average of $0.77. Evogene has a one year low of $0.45 and a one year high of $1.44. The firm has a market cap of $26.58 million, a price-to-earnings ratio of -1.40 and a beta of 1.40.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings data on Thursday, May 23rd. The biotechnology company reported ($0.08) EPS for the quarter. Evogene had a negative net margin of 233.66% and a negative return on equity of 70.96%. The business had revenue of $4.19 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Evogene stock. BNP Paribas Financial Markets raised its position in Evogene Ltd. (NASDAQ:EVGN) by 30.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 21,500 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.22% of Evogene worth $69,000 as of its most recent SEC filing. 10.40% of the stock is owned by institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.